Health data firm Sophia Genetics raises $77M to support U.S. expansion

Medicine Money
Sophia Genetics estimates its AI platform is currently used by more than 850 hospitals and in the diagnosis of over 300,000 patients. (Getty/utah778)

Swiss big data startup Sophia Genetics has raised $77 million in new venture capital to help fund its expansion to its new U.S. location and bring on more staff.

The series E round was led by Generation Investment Management, a sustainable investment management firm co-founded and chaired by former Vice President Al Gore, with participation from Idinvest Partners and Sophia’s previous backers Balderton Capital and Alychlo.

The new money, which brings the Lausanne, Switzerland-based company’s fundraising total up to $140 million, will also be used to help push its artificial intelligence-based platform into new hospital systems.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Sophia Genetics’ analysis platform aims to digest genomic and radiomic data to assist in the diagnosis of patients with cancer and hereditary disorders. The company said its Sophia AI program is currently employed by more than 850 hospitals in 77 countries and has been used in the diagnosis of over 300,000 patients.

“Generation are delighted to partner with Sophia Genetics,” said Lilly Wollman, co-head of Generation’s growth equity team, in a statement. “We believe that leveraging genetic sequencing and advanced digital analysis will enable a more sustainable healthcare system.”

Last September, in announcing its new headquarters in Boston, Sophia Genetics founder and CEO Jurgi Camblong said the company had about 20 employees in the country, with plans to grow to at least 50 over the next year, as it continues supporting at least 100 university hospitals in the U.S.

Suggested Articles

Nektar Therapeutics created Inheris Biopharma, a new subsidiary that will take over the launch of Nektar’s pain drug, NKTR-181.

Using liver “organoids,” a Dutch team has gained insight into how the mutated BAP1 gene contributes to liver cancer.

The VC shop, which backed Inflazome with its second fund, will pump most of the money into European biopharma and medtech companies.